We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines.
- Authors
Mariz, Filipe Colaço; Bender, Noemi; Anantharaman, Devasena; Basu, Partha; Bhatla, Neerja; Pillai, Madhavan Radhakrisna; Prabhu, Priya R.; Sankaranarayanan, Rengaswamy; Eriksson, Tiina; Pawlita, Michael; Prager, Kristina; Sehr, Peter; Waterboer, Tim; Müller, Martin; Lehtinen, Matti
- Abstract
We performed an independent comparison of neutralizing and cross-neutralizing antibody (ab) levels seven months after initiation of three-dose, six-month vaccination schedules with the bivalent and quadrivalent human papillomavirus (HPV) vaccines in adolescent Finnish and Indian females, respectively. We used a semi-automated Pseudovirion-Based Neutralization Assay and observed significantly higher HPV16/18 peak ab-levels in bivalent as compared to quadrivalent vaccine recipients. Bivalent vaccine induced cross-neutralizing HPV31/33/45/52/58 antibodies significantly more frequently and to higher levels than the quadrivalent vaccine. The correlation of bivalent vaccine-induced HPV45 ab-levels with HPV16/18 ab-levels was stronger than that of corresponding quadrivalent vaccine-induced ab-levels, suggesting a qualitatively different cross-reactive response. Our findings on the comparison of the immunogenicity of two HPV vaccine tested in two different populations indicate that further head-to-head studies are warranted.
- Subjects
PAPILLOMAVIRUSES; HUMAN papillomavirus vaccines; IMMUNOGLOBULINS; HIV-positive persons; SEROPREVALENCE
- Publication
NPJ Vaccines, 2020, Vol 5, Issue 1, p1
- ISSN
2059-0105
- Publication type
Article
- DOI
10.1038/s41541-020-0165-x